Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This appears to be a combination ophthalmic medication containing four active ingredients: - **Nepafenac**: A nonsteroidal anti-inflammatory drug (NSAID) prodrug that reduces pain and inflammation, particularly after cataract surgery - **Tobramycin**: An aminoglycoside antibiotic that treats bacterial infections - **Dexamethasone**: A corticosteroid that reduces inflammation - **Tropicamide**: An anticholinergic agent that causes pupil dilation (mydriasis) and paralysis of accommodation (cycloplegia) This combination would likely be used in the context of ophthalmic surgery, particularly cataract surgery, to simultaneously address inflammation, prevent infection, and facilitate examination or surgical procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nepafenac + tobramycin + dexamethasone + tropicamide.